Health Care & Life Sciences » Biotechnology | Blueprint Medicines Corp.

Blueprint Medicines Corp.

Blueprint Medicines Corp.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
43.89 M
Public Float
36.97 M
Blueprint Medicines Corp.
Stock Exchange NASDAQ Stock Market
EPS
$6.08
Market Cap
$4.68 B
Shares Outstanding
48.85 M
Public Float
42.04 M

Profile

Address
45 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.blueprintmedicines.com
Updated 07/08/2019
Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia.

Financials

View All
Created with Highcharts 5.0.14Blueprint Medicines Corp.Net Income. Fiscal year is January-December. All values USD Thousands.20 91220 91240 28540 28552 76952 76972 49572 495148 119148 119236 642236 642201320142015201620172018050k100k150k200k250k
Created with Highcharts 5.0.14Blueprint Medicines Corp.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.000011 40011 40027 77227 77221 42621 42644 52144 521201320142015201620172018010k20k30k40k50k

Jeffrey W. Albers
President, Chief Executive Officer & Director
Daniel S. Lynch
Director